• 1073 Citations
  • 15 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Colin Murdoch obtained his doctorate under the supervision of Prof Ajay Shah through the British Heart Foundation 4-year Ph.D program at the BHF Cardiovascular Centre of Excellence, King’s College London. He investigated the “Influence of endothelial NADPH oxidase on cardiac fibrosis and remodelling in the hypertensive heart.”  utilising murine cardiovascular techniques such as pressure-volume loops, echocardiography and telemetry.

Dr Murdoch conducted post-doctoral training with Richard Cohen and Reiko Matsui at the Whitaker Cardiovascular Institute, Boston University investigating redox signalling in neovascularisation in type-2 diabetes. He moved back to the UK and was awarded a highly competitive Marie Skłodowska-Curie International Incoming Fellowship to transfer in vivo cardiovascular phenotyping techniques to Aston Medical School working in Prof Asif Ahmed’s laboratory.

Previously he worked as a functional pharmacologist for 5-years at Asterand Biosceince after gaining his honours degree in Pharmacology with Industrial Experience at University of Edinburgh.

Dr Murdoch joined the faculty at School of Medicine, University of Dundee in March 2018.  His research focuses on the pathophysiological role of redox signalling in cardiovascular disease including preeclampsia and peripheral artery disease.   Dr Murdoch is the project coordinator for EU Horizon2020 Innovative training network, iPLACENTA.  Involving a collaborative training network between 11 institutes across Europe.


Dr Murdoch’s research aims to understand the pathophysiological role of redox signalling in cardiovascular disease, focusing on signalling in the endothelium.  Currently he is investigating how oxidative post-translational modification of thiols contribute to the preeclampsia phenotype. 


Dr Murdoch is the coordinator of iPLACENTA, a €3.9 million Horizon 2020 innovative training network (ITN).   A multi-disciplinary network of 11 European partners delivering post-graduate training for 15 Early stage researchers (ESRs/Ph,D).  The principal research aim of iPLACENTA is to improve the ability to study, model and visualise the placenta to enhance investigation and prognosis of complicated pregnancies such as preeclampsia and intrauterine growth restriction.   Integrating organ-chip technology and mathematical modelling, with innovation in visualising and assessing placenta health in the clinic and pre-clinical models.   The research will interconnect to unlock the complexity of placental disease, providing mechanistic clues for complex diseases, new ways to model placenta function, validate novel clinical diagnostic tools and characterise in vivo pre-clinical models.   The PhD training programme aims to equip the ESRs with the necessary skills to meet the challenges of cutting-edge translational research alongside topics such as OpenScience, entrepreneurship, project management and business skills.   See  www.iplacenta.eu


Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

NADPH Oxidase Medicine & Life Sciences
Glutaredoxins Medicine & Life Sciences
Reactive Oxygen Species Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Oxidation-Reduction Medicine & Life Sciences
Vascular Endothelial Growth Factor Receptor-1 Medicine & Life Sciences
Endothelial Cells Medicine & Life Sciences
Pre-Eclampsia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2018 2021

Research Output 2004 2019

IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages

Weinberg, E. O., Ferran, B., Tsukahara, Y., Hatch, M. M. S., Han, J., Murdoch, C. E. & Matsui, R., 25 Jan 2019, In : PLoS ONE. 14, 1, 15 p., e0210827.

Research output: Contribution to journalArticle

Open Access
3 Citations

Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor

Wang, Z., Stuckey, D. J., Murdoch, C. E., Camelliti, P., Lip, G. Y. H. & Griffin, M., 27 Apr 2018, In : Cell Death and Disease. 9, 6, p. 613 12 p., 613.

Research output: Contribution to journalArticle

Open Access
transglutaminase 2
Heart Rupture
Angiotensin II

Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review

Guo, D., Murdoch, C. E., Liu, T., Qu, J., Jiao, S., Wang, Y., Wang, W. & Chen, X., 26 Apr 2018, In : Frontiers in Pharmacology. 9

Research output: Contribution to journalReview article

Open Access

Differential regulation of ischemic limb vascularization and tumor growth by endothelial glutaredoxin-1

Yura, Y., Johnson, R., Watanabe, Y., Tsukahara, Y., Ferran, B. P., Murdoch, C., van der Velden, J., Bachschmid, M. M., Heininger, Y. J. & Matsui, R., Nov 2017, In : Free Radical Biology and Medicine. 112, 1, p. 38-39

Research output: Contribution to journalMeeting abstract

12 Citations

Distinct regulatory effects of myeloid cell and endothelial cell Nox2 on blood pressure

Sag, C. M., Schnelle, M., Zhang, J., Murdoch, C. E., Kossmann, S., Protti, A., Santos, C. X. C., Sawyer, G. J., Zhang, X., Mongue-Din, H., Richards, D. A., Brewer, A. C., Prysyazhna, O., Maier, L. S., Wenzel, P., Eaton, P. J. & Shah, A. M., 15 Mar 2017, In : Circulation. 135, 22, p. 2163-2177 15 p.

Research output: Contribution to journalArticle

Open Access
Myeloid Cells
Endothelial Cells
Blood Pressure
Angiotensin II
NADPH Oxidase


Aston Achievement Awards Excellent Research

Colin Murdoch (Recipient), 1 Jan 2017

Prize: Prize (including medals and awards)

Transgenic Mice
Blood Vessels
Cardiovascular Diseases

Marie Skłodowska-Curie International Incoming Fellow

Colin Murdoch (Recipient), 1 May 2014

Prize: Fellowship awarded competitively

Medical Schools